Search

Positive RUBY phase III data show potential for Jemperli (dostarlimab) combinations in more patients with primary advanced or recurrent endometrial cancer

Media

Only immuno-oncology combination to show statistically significant and clinically meaningful overall survival in overall population.

https://www.gsk.com/en-gb/media/press-releases/positive-ruby-phase-iii-data-show-potential-for-jemperli-dostarlimab-combinations-in-more-patients-with-primary-advanced-or-recurrent-endometrial-cancer/

First published: 16 March 2024

History and heritage

Company

It began when Plough Court Pharmacy was established in 1715. Discover GSK’s journey to the company we are today

https://www.gsk.com/en-gb/company/history-and-heritage/

First published: 16 December 2024

GSK unveils latest research advances demonstrating strength of its portfolio and pipeline at ASCO and EHA

Media

GSK plc will present 25 abstracts at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

https://www.gsk.com/en-gb/media/press-releases/gsk-unveils-latest-research-advances-at-asco-and-eha/

First published: 26 May 2022

New data at ASCO showcases the transformational potential of GSK's oncology portfolio

Media

Pivotal data will be shared from the DREAMM-8 and DREAMM-7 phase III trials.

https://www.gsk.com/en-gb/media/press-releases/new-data-at-asco-showcases-the-transformational-potential-of-gsks-oncology-portfolio/

First published: 23 May 2024